US Stock MarketDetailed Quotes

PRLD Prelude Therapeutics

Watchlist
  • 2.770
  • -2.060-42.65%
Close Sep 13 16:00 ET
  • 2.800
  • +0.030+1.08%
Post 19:53 ET
152.42MMarket Cap-1564P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    9 hours ago
    NEWS
    $Prelude Therapeutics (PRLD.US)$
    Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
    Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
    - 3 confirmed partial re...
    Stock Region
    Stock Region
    Jul 10 10:17
    Therapeutics Company Announces Major Clinical Collaboration With Merck
    Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
    On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...
    Trytosaveabit
    Trytosaveabit
    Jul 9 06:31
    Update
    $Prelude Therapeutics (PRLD.US)$ Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
    1
    Jaguar8
    Jaguar8
    Jul 9 06:30
    NEWS
    $Prelude Therapeutics (PRLD.US)$
    Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
    Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...
    Mr Long Term
    Mr Long Term
    Jun 22 21:57
    Columns Wall Street's Top 10 Call This Week.
    Wall Street experts reveal the five stocks to buy, five stocks to sell this week
    What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
    Top 5 Buy Calls:
    1. Skyworks upgraded to Buy at B. Riley
    $Skyworks Solutions (SWKS.US)$
    B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
    Wall Street's Top 10 Call This Week.
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data